Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann, M.D., will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, at 3:55 pm Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann, M.D., will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, at 3:55 pm Eastern Time. The webcast will be accessible through the company's Investor Relations section. Immunovant focuses on developing therapies for autoimmune diseases, particularly with FcRn inhibitor technology, addressing significant patient needs.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +5.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th-15th, 2022.
| Guggenheim 4th Annual Immunology and Neurology Day fireside chat details: | |
| Date: | Monday, November 14th, 2022 |
| Time: | 3:55 pm Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com. |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. For additional information on the Company, please visit www.immunovant.com.
Contact:
Chau Cheng, PhD, MBA
Vice President, Investor Relations
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.